The Advisory Committee provides oversight of the project on behalf of the research team and helps guide it towards success. The specific roles of the Advisory Committee include: reviewing the activity, timelines, milestones, and deliverables, and commenting and advising on actions needed to ensure each workstream is meeting its responsibilities. Throughout the development of the project, the Advisory Committee will review iterations of the mobile application from the Minimal Viable Product through to the final prototype to be tested. The committee will provide advice on international perspectives and issues such as regulatory approvals needed to approve the mobile application beyond Australian context. They will also provide high level advice on how the device may be implemented in both private and public health sectors. Once the mobile application has been moved to feasibility testing in 2024-2025, the committee will also advise on actions needed to meet recruitment rates and regular reports of the various components of the project, and review adverse events and serious adverse events.
Name of Member | Role in AC | Institution |
Prof Michael Fine | Co-Chair | Macquarie University |
Dr Sanka Amadoru | Co-Chair | Austin Health |
Prof Felicity Baker | Principal Investigator | University of Melbourne |
Prof Nicola Lautenschlager | Chief Investigator | University of Melbourne |
Prof Irene Blackberry | Independent Investigator | La Trobe University |
Prof Claudia Cooper | Independent Investigator | Queen Mary University London |
Dr Francine Moss | Independent Investigator | St Vincent’s Melbourne |
Robyn Attoe | Industry Partner | Bupa |
Valda Groves | Industry Partner | Victorian Department of Health |
Dr Tom Morris | Industry Partner | The Dementia Centre, HammondCare |
Sarah Yeates | Industry Partner | Caladenia Dementia Care |
Judy Lowthian | Industry Partner | Bolton Clarke Research Institute |
Barry Baulch | Consumer Representative | |
Asami Koike | AC Coordinator | University of Melbourne |